Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Timing of birth and risk of multiple sclerosis: population based study.
Overview of the immune system.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?
Autoimmune sleep disorders.
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD.
10 years of interferon beta-1b (Beta feron therapy.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Immunology 2016
Myelin Gordon Research Conference
Convergence through Complexity: How to Cure Brain Disease; Orion Bionetworks 2nd Annual Conference
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Flupirtine in pain management: pharmacological properties and clinical use.
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
Evaluation of quality of life and fatigue in radiologically isolated syndrome.
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Atypical facial pain in multiple sclerosis caused by spinal cord seizures: a case report and review of the literature.

Pages